Intralytix Receives Multimillion-Dollar Clinical Trial Award From NIAID to Manage Shigella Infections in Humans
COLUMBIA, Md., May 4, 2020 Intralytix, Inc. announced today that it has received a multimillion-dollar grant (AI 148054) from the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), for the clinical development of its bacteriophage therapy preparation for managing infections caused by the bacterial pathogen Shigella. Dr. Alexander Sulakvelidze, Executive Vice President of Intralytix and the Program Director of the multi-PI grant, commented, “We are very pleased to have this collaborative opportunity with NIAID.
Image: https://biobuzz.inloop.com
{iframe}https://biobuzz.inloop.com/en/article/80146?utm_source=Mailjet-biobuzz&utm_medium=newsletter&utm_campaign=biobizHub-781-s-en-060520{/iframe}